Targeting Triglyceride Metabolism for Colorectal Cancer Prevention and Therapy

Nagendra Yarla1, Venkateshwar Madka1, Chinthalapally Rao1,2

  • 1Center for Cancer Prevention and Drug Development, Medical Oncology, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104; USA.

Current Drug Targets
|August 25, 2021
PubMed
Abstract

Insights

Triglyceride metabolism is altered in colorectal cancer (CRC), with anabolic pathways upregulated and catabolic pathways downregulated. This suggests TG profiling may offer new diagnostic and therapeutic strategies for CRC.

Area of Science:

  • Biochemistry
  • Oncology
  • Metabolomics

Background:

  • Triglycerides (TG) are crucial for energy storage and are linked to colorectal cancer (CRC) development.
  • Key enzymes in TG metabolism, such as TG lipase and fatty acid synthase, are implicated in CRC initiation and progression.

Purpose of the Study:

  • To investigate the role of triglyceride metabolism in colorectal cancer (CRC).
  • To explore the potential of TG profiling as a biomarker for CRC diagnosis and prognosis.

Main Methods:

  • Comprehensive literature review on TG metabolism and CRC.
  • Analysis of transcriptomic and proteomic data from The Cancer Genome Atlas (TCGA) database for TG metabolic pathway mediators.
  • Utilized R program and cBioportal software for data analysis.

Main Results:

  • Dysregulation of TG metabolism is significantly associated with CRC initiation and progression.
  • TG anabolic pathway mediators are generally overexpressed in CRC, while catabolic pathway mediators are downregulated.
  • Metabolic enzymes involved in TG and fatty acid pathways play a role in CRC tumor growth, survival, and metastasis.

Conclusions:

  • TG profiling shows promise as a biomarker for CRC diagnosis and/or prognosis.
  • Further investigation into TG-associated lipid metabolic pathways is warranted for developing novel CRC preventive and therapeutic strategies.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
986
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
70
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
277
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290